'Always average down with biotech start-up stock when there hasn't been any fundamental change since the market doesn't know how to correctly value them until the end game.'
Very high-risk strategy. Sure, early-stage biotechs can be underpriced, especially with no revenue and lots of uncertainty, but they also frequently go to zero.
Averaging down might work, but it's far from safe.
Add to My Watchlist
What is My Watchlist?
